Skip to main content
SpringerLink
Log in

The significance of fetal maxillary length in the first trimester screening for trisomy 21

  • Materno-fetal Medicine
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objective

The present study aims to specify the significance of fetal maxillary length by establishing a nomogram for a Turkish population and by investigating its relationship with the ultrasonographic and biochemical parameters which are commonly used to screen trisomy 21 in the first trimester of pregnancy.

Methods

The present observational study investigates 1,308 Turkish women who had 11- to 14-week-old singleton healthy pregnancies. Fetal crown-rump length (CRL), nuchal translucency (NT), nasal bone length (NBL) and maxillary length are measured by ultrasonography and maternal serum concentrations of pregnancy-associated plasma protein-A (PAPP-A) and free beta-human chorionic gonadotropin (HCG) are determined.

Results

A positive and significant correlation was detected between the fetal maxillary length and gestational age (r = 0.309, P < 0.001) as was the case with fetal CRL (r = 0.357, P < 0.001) and NBL (r = 0.487, P < 0.001). Although there was a significant and positive correlation between fetal maxillary length and maternal serum PAPP-A levels (r = 0.201, P < 0.001), a significant and negative correlation was found between fetal maxillary length and the maternal serum concentrations of free beta-HCG (r = −0.238, P < 0.001). Fetal maxillary length increased in accordance with the advancing gestational age and increasing CRL. Maternal serum PAPP-A concentrations and fetal CRL and NBL were addressed as independent predictors of fetal maxillary length.

Conclusions

The length of fetal maxillary bone is a promising biometrical parameter which can be reliably and efficiently used to screen trisomy 21 in first trimester. Fetal maxillary length is also found to correlate with gestational age, CRL, NBL and PAPP-A significantly. It would be rational to use a combination of nasal and maxillary bone length measurements in case serum concentrations of PAPP-A or beta-HCG cannot be assessed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nicolaides KH (2003) Screening for chromosomal defects. Ultrasound Obstet Gynecol 21:313–321

    Article  PubMed  CAS  Google Scholar 

  2. Nicolaides KH, Wegrzyn P (2005) First trimester diagnosis of chromosomal defects. Ginekol Pol 76:1–8

    PubMed  Google Scholar 

  3. Farkas LG, Katic MJ, Forrest CR, Litsas L (2001) Surface anatomy of the face in Down’s syndrome: linear and angular measurements in the craniofacial regions. J Craniofac Surg 12:373–379

    Article  PubMed  CAS  Google Scholar 

  4. Lomholt JF, Russell BG, Stoltze K, Kjaer I (2002) Third molar agenesis in Down syndrome. Acta Odontol Scand 60:151–154

    Article  PubMed  Google Scholar 

  5. Shapira J, Chaushu S, Becker A (2000) Prevalence of tooth transposition, third molar agenesis, and maxillary canine impaction in individuals with Down syndrome. Angle Orthodontists 70:290–296

    CAS  Google Scholar 

  6. Goldstein I, Reiss A, Rajamim BS, Tamir A (2005) Nomogram of maxillary bone length in normal pregnancies. J Ultrasound Med 24:1229–1233

    PubMed  Google Scholar 

  7. Nicolaides KH (2004) Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 191:45–67

    Article  PubMed  Google Scholar 

  8. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K (2001) Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational study. Lancet 358:1665–1667

    Article  PubMed  CAS  Google Scholar 

  9. Orlandi F, Bilardo CM, Campogrande M, Krantz D, Hallahan T, Rossi C, Viora E (2003) Measurement of nasal bone length at 11–14 weeks of pregnancy and its potential role in Down syndrome risk assessment. Ultrasound Obstet Gynecol 22:36–39

    Article  PubMed  CAS  Google Scholar 

  10. Cicero S, Curcio P, Rembouskos G, Sonek J, Nicolaides KH (2004) Maxillary length at 11–14 weeks of gestation in fetuses with trisomy 21. Ultrasound Obstet Gynecol 24:19–22

    Article  PubMed  CAS  Google Scholar 

  11. Polat N, Yazici G, Polat Y, Unlu A (2005) The median free β-hCG nd PAPP-A levels in Mersin area and their association with pregnancy complications. J Turkish Clin Biochem 3(3):117–123

    Google Scholar 

  12. Ozer A, Ozaksit G, Kanat-Pektas M, Ozer S (2010) First trimester examination of fetal nasal bone in the Turkish population. J Obstet Gynaecol Res (published online 23 April 2010). doi:10.1111/j.1447-0756.2010.01182

  13. Orup HI Jr, Holmes LB, Keith DA, Coul BA (2003) Cranifacial skeletal deviations following in utero exposure to the anticonvulsant phenytoine: monotherapy and polytherapy. Orthod Craniofac Res 6:2–19

    Article  PubMed  Google Scholar 

  14. Bohlandt S, von Kaisenberg CS, Wewetzer K, Christ B, Nicolaides KH, Brand-Saberi B (2000) Hyaluronan in the nuchal skin of chromosomally abnormal fetuses. Hum Reprod 15:1155–1158

    Article  PubMed  CAS  Google Scholar 

  15. Howe AM, Hawkins JK, Webster WS (2004) The growth of the nasal septum in the 6–9 week period of foetal development. Warfarin embryopathy offers a new insight into prenatal facial development. Aust Dent J 49:171–176

    Article  PubMed  CAS  Google Scholar 

  16. Leung TY, Chan LW, Leung TN, Fung TY, Sahota DS, Lau TK (2006) First-trimester maternal serum level of pregnancy-associated plasma protein-A is an independent predictor of fetal maxillary bone length. Ultrasound Obstet Gynecol 27:9–12

    Article  PubMed  CAS  Google Scholar 

  17. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K et al (2005) First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 353:2068–2070

    Article  Google Scholar 

  18. Miyakoshi N, Qin X, Kasukawa Y, Richman C, Srivastava AK, Baylink DJ, Mohan S (2001) systemic administration of insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism. Endocrinology 142:2641–2648

    Article  PubMed  CAS  Google Scholar 

  19. Ortiz CO, Chen BK, Bale LK, Overgaard MT, Oxvig C, Conover CA (2003) Transforming growth factor-beta regulation of the insulin-like growth factor binding protein-4 protease system in cultured human osteoblasts. J Bone Miner Res 18:1066–1072

    Article  PubMed  CAS  Google Scholar 

  20. Bunn RC, Green LD, Overgaard MT, Oxvig C, Fowlkes JL (2004) IGFBP-4 degradation by pregnancy-associated plasma protein-A in MC3T3 osteoblasts. Biochem Biophys Res Commun 325:698–706

    Article  PubMed  CAS  Google Scholar 

  21. Monget P, Mazerbourg S, Delpuech T, Maurel MC, Maniere S, Zapf J, Lalmanach G, Oxvig C, Overgaard MT (2003) Pregnancy-associated plasma protein-A is involved in insulin–like growth factor binding protein-2 (IGFBP-2) proteolytic degradation in bovine and porcine preovulatory follicles: identification of cleavage site and characterization of IGFBP-2 degradation. Biol Reprod 68:77–86

    Article  PubMed  CAS  Google Scholar 

  22. Laursen LS, Overgaard MT, Soe R, Boldt HB, Sottrup-Jensen L, Giudice LC, Conover CA, Oxvig C (2001) Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett 504:36–40

    Article  PubMed  CAS  Google Scholar 

  23. Prefumo F, Sairam S, Bhide A, Penna L, Hollis B, Thilaganathan B (2004) Maternal ethnic origin and fetal nasal bones at 11–14 weeks of gestation. BJOG 111:109–112

    PubMed  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Department of Perinatology, Dr. Zekai Tahir Burak Women Health Research and Education Hospital, Ankara, Turkey

    Naim Unsal, Mustafa Ozat, Mine Kanat-Pektas, Tayfun Gungor & Nuri Danisman

  2. Yunus Emre Mah., Dereboyu Sok. No: 71/2 Yenimahalle, 06170, Ankara, Turkey

    Mine Kanat-Pektas

Authors
  1. Naim Unsal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mustafa Ozat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mine Kanat-Pektas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tayfun Gungor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nuri Danisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mine Kanat-Pektas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Unsal, N., Ozat, M., Kanat-Pektas, M. et al. The significance of fetal maxillary length in the first trimester screening for trisomy 21. Arch Gynecol Obstet 283, 1199–1205 (2011). https://doi.org/10.1007/s00404-010-1527-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-010-1527-9

Keywords

Search

Navigation